Physician profile
Mitchell Kaplan
NPI 1760536130
$5,718.76
in general payments reported to CMS, 2019-2025
37 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $175 · 2021: $615 · 2022: $578 · 2023: $1,009 · 2024: $1,710 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226 · Travel and Lodging: $383 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.27 |
| Travel and Lodging | $382.95 |
| Education | $205.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,040.93 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,018.82 | 2019-2025 | |
| Boston Scientific Corporation | $678.12 | 2024-2025 | Axios, Spyglass, Alliance II |
| Takeda Pharmaceuticals U.S.A., INC. | $467.84 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $386.02 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.66 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $229.56 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $218.81 | 2021-2025 | |
| Lilly USA, LLC | $183.97 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $102.55 | 2019-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $100.10 | 2019-2023 | Sutab, Suflave |
| Vivus LLC | $96.45 | 2021-2022 | |
| Genzyme Corporation | $88.38 | 2022-2025 | |
| Madrigal Pharmaceuticals | $70.00 | 2024-2025 | Resmetirom, Rezdiffra |
| Intercept Pharmaceuticals, INC. | $69.51 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $67.20 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $51.14 | 2019-2023 | Linzess |
| Ucb, INC. | $48.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $47.81 | 2019-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.66 | 2023 | Cyltezo |
| Steris Corporation | $40.47 | 2024 | |
| Nestle Healthcare Nutrition INC. | $40.06 | 2021 | |
| Romark Laboratories, Lc | $38.44 | 2019-2020 | |
| Apollo Endosurgery US INC | $26.38 | 2022-2023 | Orbera Intragastric Balloon System |
| Organon LLC | $23.74 | 2022 | |
| Ambu INC. | $23.48 | 2020-2021 | |
| Ardelyx, INC. | $20.59 | 2024 | Ibsrela |
| Evoke Pharma, INC. | $17.87 | 2022 | |
| Celltrion USA INC. | $17.86 | 2024 | Vegzelma |
| Shire North American Group INC | $17.02 | 2019 | |
| Pfizer INC. | $15.47 | 2019 | |
| Ethicon US, LLC | $15.25 | 2019 | |
| Exact Sciences Corporation | $14.68 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $13.99 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.91 | 2019 | |
| Endogastric Solutions, INC | $10.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$53,998.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.